Practical Recommendations in Immuno and Molecular Oncology (PRIMO)
February 22-25, 2023
Honolulu, HI
DISCLOSURE INDEX
The Medical Educator Consortium, Inc. in accordance with the Joint Accreditation Criteria and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, has implemented a process where everyone who is in a position to control the content of a CME/CE activity has disclosed to us all relevant financial relationships with any ineligible company that they have had over the past 24 months. There is no minimum financial threshold; disclosure must be made regardless of whether the person views the financial relationships as relevant to the education. The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners.
As a Joint Accreditation (JA) Provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All individuals who are in a position to control the content of this educational activity have disclosed all relevant financial relationships with any ineligible companies to the provider. This disclosure includes all persons in control of content to include staff and educational committee members involved in the planning process.
The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.
As a Joint Accreditation (JA) Provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All individuals who are in a position to control the content of this educational activity have disclosed all relevant financial relationships with any ineligible companies to the provider. This disclosure includes all persons in control of content to include staff and educational committee members involved in the planning process.
The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.
Speakers/Moderators – Reported Relevant Financial Disclosure(s)
Sanjiv S. Agarwala, MD
Has no relevant financial relationships
Paolo A. Ascierto, MD
Grant/Research Support: BMS, Roche-Genentech, Array/Pfizer, Sanofi
Consultant: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP
Has no relevant financial relationships
Elizabeth Brem, MD
Grant/Research Support: Kowa Pharmaceuticals
Consultant: Acrotech Biopharma, BeiGene, Pharmacylics
Speakers’ Bureau: SeaGen, Incyte/Morphosys, BeiGene, Astra Zeneca, Pharmacyclics/Janssen
Advisory Board: ADC Therapeutics, Bayer, BeiGene
Don S. Dizon, MD, FACP, FASCO
Grant/Research Support: Bristol-Myers, Pfizer, Johnson and Johnson
Consultant: Astra-Zeneca, Clovis
Stock Shareholders: Midi
Jami Fukui, MD
Has no relevant financial relationships
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Grant/Research Support: Pharmacosmos
William J. Gradishar, MD, FACP
Grant/Research Support: Roche/Genentech
Consultant: DMC Seattle Genetics, Genentech, Immunomedics, Astra-Zeneca/Daiichi
Petros Grivas, MD, PhD
Grant/Research Support: Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck & Co., Mirati Therapeutics, Pfizer, QED Therapeutics
Consultant: AstraZeneca, Astellas Pharma, Boston Gene, Bristol Myers Squibb, Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech/Roche, Gilead Sciences, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, Merck & Co., Mirati Therapeutics, Pfizer, PureTech, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, 4D Pharma PLC, UroGen
Hyunseok “Hyu” Kang, MD, MPH, FACP
Grant/Research Support: Eli-Lilly, Exelixis, Elevar Therapeutics
Consultant: Bayer, Tempus, Coheres Biosciences, Bertis
Andrew H. Ko, MD, FASCO
Grant/Research Support: Apexigen, Abgenomics, Astellas, LEAP Therapeutics, Celgene, Merck, Roche/Genentech, BMS, Biomed Valley, Crystal Genomics
Consultant: DMC Roche/Genentech, Ipsen, Erytech.
Advisory Board: Five Prime, Tyme, Turning Point Therapeutics, Signatera, Syros, Genentech (All Ended)
Catherine Lai, MD, MPH
Grant/Research Support: Jazz Pharma
Consultant: Jazz Pharma, Genentech, Novartis, Taiho, Pfizer, PDS Biotechnology, Macrogenics, Astellas
Speakers’ Bureau: Jazz Pharma, Astellas (Both ended Dec 2021)
Ravi A. Madan, MD
Grant/Research Support: Bayer
Reshma L. Mahtani, DO
Grant/Research Support: Astra Zeneca, Genentech/Roche, Veru
Consultant: Agendia, Amgen, Astra Zeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, SeaGen
Stock/Shareholder: Merck
Matthew Matasar, MD
Grant/Research Support: Genentech Roche Glaxo Smith Kline, IGM Biosciences, Bayer, Pharmacyclis, Janssen, Rocket Medical, Seattle Genetics, Immunovaccine Technologies
Consultant: Genentech, Bayer, Merck, Juno Therapeutics, Roche, Teva, Rocket Medical, Seattle Genetics, Daiichi Sankyo, Takeda, Epizyme
Ashwin Mehta, MD, MPH
Has no relevant financial relationships
Shane Y. Morita, MD, MS, PhD, FACS
Has no relevant financial relationships
Jorge J. Nieva, MD
Grant/Research Support: Genentech, Merck
Consultant: Aadi Biosciences, Astra Zeneca, Bristol Myers Squibb, Fujirebio, G1 Therapeutics, Genentech, Mindmed, Naveris, Takeda, Western Oncolytics
Stock Shareholders: Cansera, Epic Sciences, Indee Bio, Quantgene
Other: Intellectual Property: Cansera
Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS
Grant/Research Support: Corcept Therapeutics
Consultant: GSK, AstraZeneca, Clovis, Merck, Genentech
Mark Pegram, MD
Consultant: Gilead, AstraZeneca, Roche, Hologic, SeaGen
Luis E. Raez, MD FACP FCCP
Grant/Research Support: BMS, Merck, Pfizer, Genetech, Velos, Guardant Health, Natera, Syndax, AstraZeneca, Novartis, Bio Alta, AnHeart
Hope S. Rugo, MD, FASCO
Grant/Research Support: Pfizer, Merck, Novartis, Lilly, Roche, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, AstraZeneca, Ayala, Astellas and Gilead
Speakers’ Bureau: Puma, Samsung, Chugai, Blueprint
Ritu Salani MD, MBA
Speakers’ Bureau: Merck
Advisory Board: Regeneron, Arcus biologics, Instil Bio, Merck, Immunogen, Clovis, Seagen, Mersana, GSK, Genentech, Agenus
Edgardo S. Santos Castillero, MD, FACP
Consultant: Amgen, AstraZeneca, EMD Serono, Pfizer, Mirati, Genentech, Regeneron, Lilly, Boehringer-Ingelheim, Catalyst Pharmaceutical
Speakers’ Bureau: Amgen, Astrazeneca, EMD Serono, Pfizer, Genentech, Regeneron, Lilly, Boehringer-Ingelheim, Astellas, Merck, Novartis, Takeda, Sanofi, Jazz Pharmaceutical, G1 Therapeutics
Amy Schippers, PA-C
Has no relevant financial relationships
Rachna T. Shroff, MD, MS
Grant/Research Support: Bayer, BMS, Bristol-Myers Squibb, Exelixis Pharm., IMC Inc., LOXO, Merck, Novocure, NuCana, Pieris, QED Therapeutics, Rafael Pharm., Seagen, Taiho
Consultant: Syros
Advisory Board: AstraZeneca, Boehringer Ingelheim Pharm., CAMI, Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier, Taiho, Zymeworks Biopharm
Janakiraman Subramanian MD, MPH
Grant/Research Support: Novartis, Merck, CanStem, Helsinn, Biocept, Incyte, Genentech, Paradigm
Consultant: Astra Zeneca, Axcess, Beigene, Blueprint, Boehringer Ingelheim, Cardinal Health, Daiichi, Eli Lilly, G1 therapeutics, Janssen, Jazz Pharma, Novartis, Oncocyte, Pfizer, Takeda
Speakers’ Bureau: Astra Zeneca, Boehringer Ingelheim, G1 therapeutics, Janssen & Jazz Pharma
Saad Z. Usmani, MD, MBA, FACP
Grant/Research Support: Amgen, BMS/Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, Takeda
Consultant: Abbvie, Amgen, BMS, Celgene, Genentech, Gilead, GSK, Janssen, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
Julie M. Vose, MD, MBA
Grant/Research Support: Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Johnson & Johnson, Daichi Sankyo, Pharmacyclics, Genentech, BMS, Lilly
Consultant: Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Johnson & Johnson, Daichi Sankyo, Pharmacyclics, Genentech, BMS, Lilly
Planning Committee - Reported Relevant Financial Disclosure(s)
Sanjiv S. Agarwala, MD
Has no relevant financial relationships
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP
Has no relevant financial relationships
Don S. Dizon, MD, FACP, FASCO
Grant/Research Support: Bristol-Myers, Pfizer, Johnson and Johnson
Consultant: Astra-Zeneca, Clovis
Stock Shareholders: Midi
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Grant/Research Support: Pharmacosmos
Shane Y. Morita, MD, MS, PhD, FACS
Has no relevant financial relationships
Luis E. Raez, MD FACP FCCP
Grant/Research Support: BMS, Merck, Pfizer, Genetech, Velos, Guardant Health, Natera, Syndax, AstraZeneca, Novartis, Bio Alta, AnHeart
Hope S. Rugo, MD, FASCO
Grant/Research Support: Pfizer, Merck, Novartis, Lilly, Roche, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, AstraZeneca, Ayala, Astellas and Gilead
Speakers’ Bureau: Puma, Samsung, Chugai, Blueprint
Edgardo S. Santos Castillero, MD, FACP
Consultant: Amgen, AstraZeneca, EMD Serono, Pfizer, Mirati, Genentech, Regeneron, Lilly, Boehringer-Ingelheim, Catalyst Pharmaceutical
Speakers’ Bureau: Amgen, Astrazeneca, EMD Serono, Pfizer, Genentech, Regeneron, Lilly, Boehringer-Ingelheim, Astellas, Merck, Novartis, Takeda, Sanofi, Jazz Pharmaceutical, G1 Therapeutics
Amy Schippers, PA-C
Has no relevant financial relationships
Rachna T. Shroff, MD, MS
Grant/Research Support: Bayer, BMS, Bristol-Myers Squibb, Exelixis Pharm., IMC Inc., LOXO, Merck, Novocure, NuCana, Pieris, QED Therapeutics, Rafael Pharm., Seagen, Taiho
Consultant: Syros
Advisory Board: AstraZeneca, Boehringer Ingelheim Pharm., CAMI, Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier, Taiho, Zymeworks Biopharm
Teri Valls, CMP, CMM
Has no relevant financial relationships
Julie M. Vose, MD, MBA
Grant/Research Support: Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Johnson & Johnson, Daichi Sankyo, Pharmacyclics, Genentech, BMS, Lilly
Consultant: Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Johnson & Johnson, Daichi Sankyo, Pharmacyclics, Genentech, BMS, Lilly
CME Reviewers - Reported Relevant Financial Disclosure(s)
Sanjiv S. Agarwala, MD
Has no relevant financial relationships
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP
Has no relevant financial relationships
Lynne Davidson
Has no relevant financial relationships
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Grant/Research Support: Pharmacosmos
Amy Schippers, PA-C
Has no relevant financial relationships
Teri Valls, CMP, CMM
Has no relevant financial relationships
All of the relevant financial relationships listed for these individuals have been mitigated.
SPEAKERS WILL DIRECTLY DISCLOSE THE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL. EACH SPEAKER HAS BEEN REQUESTED TO KEEP THEIR PRESENTATION UNBIASED AND GENERIC WHEN APPLICABLE.